This startup utilizes data science and machine learning to analyze genetic data specifically related to autoimmune diseases. By identifying genetic markers and patterns, it aims to enhance understanding and treatment options for these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for treating autoimmune diseases often lack precision, leading to ineffective treatments and delayed progress in gene therapy. The complexity of genomic data and the lengthy clinical trial process contribute to the high failure rate and cost of bringing new therapies to market.
Solution
ABYA Genomics is developing a precision medicine platform that leverages AI and genomic analysis to improve the discovery and development of gene therapies for autoimmune diseases. The platform analyzes large-scale datasets from verified sources, combining AI with trusted genomic data to identify critical genetic markers. By integrating multi-omics data with custom AI models, ABYA Genomics enhances gene-editing design, optimizes vector delivery, and simulates treatment efficacy. This approach aims to accelerate the development of personalized therapies, reduce clinical trial failures, and lower the overall cost of bringing effective treatments to market.
Target Audience
The primary target audience includes researchers, pharmaceutical companies, and healthcare providers focused on developing and delivering gene therapies for autoimmune diseases.
Features
- AI-driven analysis of medical literature, clinical trials, and research papers to extract key insights on gene associations and disease mechanisms.
- Raw DNA processing using custom tools for genome alignment, variant calling, and annotations.
- Prediction of protein structures and identification of clinically relevant mutations for downstream analysis.
- Integration of multi-omics data with custom models to enhance gene-editing design.
- Optimization of vector delivery based on biological context.
- Simulation of treatment efficacy to improve clinical outcomes.